scarlet fever
Enable an AI agent to recognise and assess recorded scarlet fever episodes, distinguish them from related infections and rash illnesses, and identify evidence needed for clinical or public-health decisions.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an AI agent to recognise and assess recorded scarlet fever episodes, distinguish them from related infections and rash illnesses, and identify evidence needed for clinical or public-health decisions.
Scarlet fever is a toxin-mediated syndrome caused by pyrogenic exotoxin-producing Streptococcus pyogenes (group A Streptococcus), usually accompanying pharyngitis and characterised by fever and a diffuse, fine, sandpaper-textured erythematous rash.
It can be Compare a documented rash and infection presentation with a named, versioned scarlet fever definition.; Identify missing observations or test context that limit diagnostic confidence.; Track symptom progression, treatment received and documented response within a distinct episode.; Surface evidence requiring clinician review under an applicable escalation guideline.; Assess whether documented contacts or linked cases warrant public-health review under local rules.; Map the disease concept to verified terminology while preserving unresolved differences between clinical and surveillance definitions..
Distinguishing features
A compatible scarlatiniform rash distinguishes the scarlet fever syndrome from uncomplicated streptococcal pharyngitis; fever or sore throat alone does not establish the distinction.
Rash texture, distribution and timing must be considered with other manifestations; a red tongue or rash recorded in isolation is insufficient to identify scarlet fever.
A positive group A Streptococcus result must be interpreted alongside the syndrome because organism detection alone does not establish that it explains the rash.
The model distinguishes uncomplicated scarlet fever from suspected invasive infection using evidence of systemic deterioration, focal complications and relevant specimen results.
Alternative explanations such as viral exanthem, drug eruption and Kawasaki disease remain distinguishable hypotheses rather than being absorbed into a scarlet fever label.
Scope
+ The relationship between scarlet fever, toxin-producing group A Streptococcus and its characteristic rash syndrome
+ Clinical manifestations, temporal course and diagnostic uncertainty
+ Microbiological evidence and its relationship to the clinical presentation
+ Transmission context, linked cases and affected populations
+ Management status, recovery and complications attributable to an episode
+ Versioned disease terminology, diagnostic guidance and surveillance definitions
- The patient's complete health record and unrelated conditions
- Healthcare visits, admissions, billing and service delivery
- Group A Streptococcus taxonomy and molecular biology beyond their relevance to scarlet fever
- Streptococcal pharyngitis without the scarlet fever syndrome
- Independent models of alternative rash illnesses and invasive streptococcal disease
- Drug product specifications and general prescribing rules
Characteristics
- Diagnostic assertion status
- Suspected, supported, confirmed under a named definition, rejected, or unresolved Keeps a provisional label distinct from a diagnosis justified by specified evidence.
- Rash phenotype
- Texture, blanching, distribution, skin-fold accentuation and subsequent peeling; present, absent or not assessed for each Records the manifestation that distinguishes scarlet fever from related streptococcal illness.
- Associated clinical manifestations
- Fever, throat findings, tongue changes and other observed manifestations, each with assessment time Supports syndrome recognition without treating any single manifestation as decisive.
- Clinical timeline
- Dated observations and elapsed hours or days relative to first symptoms Connects rash onset, sampling, treatment and recovery within the same episode.
- Streptococcal test evidence
- Links to specimen site, collection time, assay type, result and laboratory interpretation Makes the strength and limitations of microbiological support assessable.
- Associated infection site
- Pharyngeal, skin or wound, other documented site, or unknown Avoids assuming that every episode has the same local infection source.
- Exposure and case linkage
- Dated contact, household, educational setting or outbreak links, with certainty Supports investigation while separating plausible exposure from demonstrated transmission.
- Treatment and response status
- Not documented, planned, started, interrupted or completed; response recorded separately Prevents a prescription from being mistaken for treatment received or recovery achieved.
- Complication status
- Not assessed, no complication identified at assessment, suspected, or established; linked to a named complication Distinguishes an uncomplicated course from findings requiring separate assessment.
- Terminology and criteria provenance
- Registry identity plus verified ICD or SNOMED concept, release, jurisdiction and applicable definition Prevents codes or diagnostic labels from silently changing meaning across revisions.
Where this came from
wikidata · CC0 1.0
Also registered as vr.tr.scarlet-fever
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 5 bundles · 9 layers · 16 findings · 27 questions.
Scarlet fever identity Defines the disease and separates its identity from related infections, coding labels and care events.
Scarlet fever can be incorrectly equated with any streptococcal throat infection or any rash accompanying a positive test.
Syndrome boundary
Establishes the relationship between the rash syndrome and its infectious cause.
Rash and streptococcal attribution
The model must represent both the compatible syndrome and the evidence attributing it to group A Streptococcus.
- What authoritative definition identifies scarlet fever and distinguishes it from streptococcal pharyngitis without a rash? definition
- What evidence supports attributing this rash to the streptococcal infection rather than a coincident illness or drug exposure? boundary
Versioned diagnostic identity
Connects the registry concept to explicit diagnostic assertions and terminology releases.
Codes and case definitions
Coding identity, clinical diagnosis and surveillance classification require separate provenance.
- Which ICD-10, ICD-11 and SNOMED concepts match this scope in the relevant releases and jurisdiction? provenance
- Which issuing body and definition version justify the recorded diagnostic or surveillance status? provenance
Rash syndrome and diagnostic evidence Organises the observed phenotype and tests used to evaluate scarlet fever.
Neither an isolated rash descriptor nor organism detection adequately captures the diagnostic reasoning.
Clinical pattern
Records the rash and associated manifestations as timed observations.
Scarlatiniform presentation
Rash texture, distribution and evolution must remain distinguishable from accompanying throat, tongue and fever findings.
- What rash texture, distribution, blanching and skin-fold changes were actually observed, and when? measurement
- How did fever, throat symptoms, tongue changes and peeling develop relative to rash onset? measurement
Testing and alternatives
Evaluates microbiological support alongside competing explanations.
Interpretable streptococcal evidence
Test interpretation requires specimen and timing information plus consideration of carriage and alternative rash causes.
- Which specimen and assay produced the result, when was it collected, and had antimicrobial treatment already begun? provenance
- What supports active streptococcal disease rather than carriage accompanying another cause of rash? boundary
- Does the applicable diagnostic guideline call for additional testing or reassessment for this age group and presentation? action
Episode course and clinical response Tracks the evolution of an episode, management received and evidence of complications.
A scarlet fever diagnosis does not by itself describe current severity, treatment completion or recovery.
Episode and treatment timeline
Connects illness milestones with documented care and response.
Progression and response
The episode needs an explicit timeline that distinguishes treatment intent, administration and observed change.
- When did symptoms begin, what treatment was actually received, and how did symptoms subsequently change? measurement
- What evidence distinguishes persistence of this episode from a new episode or a revised diagnosis? boundary
Complications and escalation
Separates expected evolution from possible local, invasive or delayed complications.
Complication attribution
Suspected complications require their own evidence, timing and attribution rather than automatic attachment to the disease label.
- Which observed findings trigger urgent assessment under the selected clinical guideline? action
- What supports linking a suspected suppurative or post-streptococcal complication to this episode? boundary
- What follow-up remains indicated by the documented course and applicable guidance? action
Transmission and population context Relates episodes to contacts, shared settings, surveillance and population evidence.
Individual diagnosis, transmission inference and outbreak classification answer different questions and require different evidence.
Exposure and infectiousness
Captures plausible transmission links and the basis for infection-control decisions.
Contact and setting assessment
Contact dates, setting and treatment timing support guideline-based assessment without assuming that a named contact caused infection.
- Which household, school or other contacts overlap the exposure period defined by the applicable guidance? measurement
- Which jurisdiction-specific guidance governs exclusion, return to activities and contact management for this episode? action
Surveillance and disease frequency
Places cases and clusters within explicitly defined surveillance populations.
Comparable case counts
Counts and rates require a population, period, case definition and ascertainment method.
- What population, age range, geography, year and case definition underlie the reported frequency? provenance
- Does the source report incidence, prevalence, notifications or an outbreak attack rate, and what denominator supports it? measurement
- What evidence and local threshold justify treating linked episodes as an outbreak or making a notification? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- This is recalled knowledge; no sources were consulted.
- Verify current diagnostic guidance, jurisdiction-specific rules and exact ICD-11 or SNOMED CT identifiers before publication.
- No prevalence estimate is supplied because it requires a defined population, period and surveillance method.
- Which of these check these first hold for the sense of scarlet fever this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- WHO ICD-10 - A38 - Scarlet fever; national clinical modifications may provide additional subcategories.
- SNOMED CT - Numeric concept identifier - The exact concept identifier and terminology edition require verification.
- Which of these identifiers and schemes hold for the sense of scarlet fever this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- WHO International Classification of Diseases provides disease classification; the revision and any national modification must accompany a code.
- CDC clinical guidance addresses testing, treatment and prevention of scarlet fever.
- UK Health Security Agency guidance addresses management of scarlet fever outbreaks in schools and childcare settings.
- Which of these standards and regulation hold for the sense of scarlet fever this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Clinical recognition of a characteristic rash associated with group A streptococcal infection.
- Microbiological investigation using throat culture, rapid antigen testing or nucleic acid amplification testing.
- Selection of antibiotic treatment for confirmed infection.
- Public health surveillance and outbreak management.
- Diagnostic coding of the condition separately from the patient and episode of care.
- Which of these real-world use hold for the sense of scarlet fever this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Incubation period - Usually 2-5 - days
- Which of these typical measurements hold for the sense of scarlet fever this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Confusion with viral exanthems, drug eruptions or other causes of fever and rash.
- A positive throat test may reflect streptococcal carriage alongside an unrelated illness; clinical context matters.
- Spread among close contacts, particularly in households and educational settings.
- Suppurative complications of the underlying infection, including peritonsillar abscess.
- Post-streptococcal complications, including acute rheumatic fever and post-streptococcal glomerulonephritis.
- Which of these failure modes and hazards hold for the sense of scarlet fever this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Notification requirements and exclusion policies vary by jurisdiction.
- Antibiotic recommendations may vary with local guidance and resistance patterns.
- Disease incidence and outbreak patterns vary by location, season and year.
- Which of these regional variation hold for the sense of scarlet fever this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Group A streptococcal pharyngitis - Scarlet fever adds the characteristic toxin-associated rash; streptococcal pharyngitis can occur without it.
- Measles - Measles is a viral infection with a different clinical pattern; organism-specific testing distinguishes it when presentation is uncertain.
- Kawasaki disease - Kawasaki disease is a systemic vasculitis that can also cause rash and strawberry tongue; persistent fever and its broader diagnostic criteria distinguish it.
- Streptococcal toxic shock syndrome - Streptococcal toxic shock syndrome involves hypotension and multiorgan involvement, rather than the usual scarlet fever syndrome.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of scarlet fever this model covers, and on what evidence? provenance
What the second pass must settle
- Which current authoritative clinical and surveillance definitions should anchor this model, and how do their confirmation requirements differ by age and jurisdiction?
- What are the verified ICD-10, ICD-11 and SNOMED mappings and release identifiers for this exact disease scope?
- How reliably are characteristic rash findings recognised across skin tones, age groups and atypical presentations, and which observations best address recognition gaps?
- Which population-specific estimates of incidence, recurrence and complications are sufficiently current and well ascertained to include?
- Which current local rules govern notification, educational-setting exclusion, return after treatment and management of linked cases?